Denali Therapeutics Inc. DNLI Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$128.45M+3.4% | -$128.55M-12.0% | -$126.9M-18.4% | -$124.12M-25.3% | -$132.97M-30.6% | ||
| $2.85M+22.4% | $2.87M+54.7% | $2.95M+60.3% | $3.05M+56.8% | $2.33M+7.5% | ||
| $23.09M-8.2% | $23.95M-4.5% | $25.14M+1.1% | $25.39M+1.1% | $25.16M-9.6% | ||
| $3.88M+247% | -$3.41M-365% | -$4.07M— | —— | -$2.64M-516% | ||
| -$22.4M-131% | $12.73M— | $1.89M-92.3% | -$4.47M+78.6% | -$9.69M-517% | ||
| $700K-25.8% | —— | —— | -$3.97M— | $943K— | ||
| -$294K— | —— | —— | —— | $0— | ||
| -$131.2M+0.2% | -$98.54M-17.7% | -$107.3M-81.4% | -$75.3M+17.5% | -$131.47M-15.7% | ||
| $2.47M-51.4% | $1.52M-70.1% | —— | $4.28M-10.6% | $5.08M+136% | ||
| $94.46M+404% | $20.77M— | $57.83M— | $157.94M— | $18.75M+104% | ||
| $12.37M— | $8.46M+102% | $0— | $0— | $0-100% | ||
| $17K-99.6% | $16K-99.8% | $1.36M-94.3% | $2.43M— | $4.36M— | ||
| —— | $81K— | $81K— | $81K— | $81K— | ||
| $219.04M+5,923% | $192.13M— | -$778K— | $1.62M-76.0% | -$3.76M-101% | ||
| $182.3M+257% | $114.36M+35.6% | -$50.24M— | $84.26M— | -$116.48M-75.1% | ||
| -$22.4M-131% | $12.73M— | $1.89M-92.3% | -$4.47M+78.6% | -$9.69M-517% | ||
| -$5.99M-130% | —— | —— | —— | $19.94M— | ||
| $1.14M+9.1% | $1.15M+9.2% | $1.14M+9.1% | $1.11M+9.1% | $1.05M+9.6% | ||
| $2.29M-92.0% | —— | —— | —— | $28.61M+52.4% | ||
| $1.26M-67.6% | $1.64M-73.4% | $2.03M-75.8% | $2.7M-73.2% | $3.89M-63.0% | ||
| -$294K— | —— | —— | —— | $0— | ||
| $17K-99.6% | $16K-99.8% | $1.36M-94.3% | $2.43M— | $4.36M— | ||
| $6.7M+1,025% | $3.22M-22.4% | $583K-89.3% | $4.06M-39.9% | $595K-41.8% | ||
| $916K+3.3% | $916K+19.6% | $900K+125% | $900K— | $887K— | ||
| $36M— | —— | —— | —— | $0— | ||
| $200M— | —— | —— | —— | $0— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$133.67M+2.1% | -$100.06M-12.7% | -$105.92M-68.1% | -$79.58M+17.1% | -$136.55M-17.9% | ||
| -$133.67M+2.1% | -$100.06M-12.7% | -$105.92M-68.1% | -$79.58M+17.1% | -$136.55M-17.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Denali Therapeutics Inc.'s cash flow data come from?
- Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.